United Therapeutics beat Q3 consensus, Tyvaso sales +17%

• United Therapeutics (NASDAQ:UTHR) Q3 results:
• Revenues: $380.1M (-5.3%) vs consensus of $357.95Mb.
• Key product sales: Remodulin: $124.5M (-26%); Tyvaso: $129.5M (+17%); Orenitram: $74.7M (+20%); Unituxin: $37.6M (+25%); Adcirca: $13.8M (-54%).
• Net Income: $171.2M (+29%); EPS: $3.84 (+28%); non-GAAP Net Income: $173M (+3%); non-GAAP EPS: $3.88 (+1%) vs consensus of $3.34.
• The company plans to launch Tyvaso for a new indication, and to launch three new products for pulmonary arterial hypertension (PAH): the Remunity Pump, the Trevyent system, and the Implantable System for Remodulin.
• https://seekingalpha.com/news/3627154-united-therapeutics-beat-q3-consensus-tyvaso-salesplus-17